Jul 28, 2022 4:15pm EDT Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2022 Financial and Operational Results on August 11, 2022
Jul 25, 2022 6:30am EDT Matinas BioPharma Announces Positive Opinion by the European Medicines Agency on Orphan Drug Designation for MAT2203 for the Treatment of Cryptococcosis
May 12, 2022 6:30am EDT Matinas BioPharma Reports First Quarter 2022 Financial Results and Operational Highlights
May 05, 2022 7:00am EDT Matinas BioPharma to Webcast Conference Call Discussing First Quarter 2022 Financial and Operational Results on May 12, 2022
May 03, 2022 7:00am EDT Matinas BioPharma to Present at the 12th Annual BioNJ BioPartnering Conference
Apr 11, 2022 7:00am EDT BioNTech and Matinas BioPharma Announce Exclusive Research Collaboration to Evaluate Novel Delivery Technology for mRNA-based Vaccines
Mar 22, 2022 7:00am EDT Matinas BioPharma to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
Mar 08, 2022 6:30am EST Matinas BioPharma Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights
